Adamant Health’s unique CE-marked data-analysis technology, based on surface electromyography and kinematic measurements, provides detailed and accurate symptom data. The easy-to-read symptom report includes a graphic visualization of the changes in the patient’s condition, an overview of the detected symptoms and their timing, and a summary of the symptoms reported by the patient.

By measuring the motor symptom itself and combining surface electromyography with motion sensor data, this future approach enables unparalleled accuracy in symptom assessment and provides clinically meaningful and actionable data for treatment planning.

Lately, the need for objective measurement to assess Parkinson's disease symptoms and treatment efficacy has emerged. Clinical assessment will continue to be essential in the diagnosis and treatment of the disease, but also modern technology, including wearable devices and artificial intelligence, will play a crucial role in the early detection of the disease and improving treatment effectiveness.

The annual congress of the European Academy of Neurology has become a premier platform for presenting cutting-edge neurological research and innovation, and exchanging knowledge. During this year's conference, a growing and active interest in the field of movement disorders, particularly Parkinson's disease, became evident with a clear call to evolve the way we diagnose and treat the disease.

Parkinson’s disease presents clinicians with unique challenges with its progressive nature and varied symptomatology. Our latest white paper explores the evolution of PD assessment methods. It presents the transformative potential of objective measurements for making better-informed decisions to improve patient outcomes.

There are many different symptoms associated with Parkinson's disease and the order in which these develop and their severity is different for each individual. Usually, the symptoms start mildly and develop gradually. Parkinson's disease symptoms are distinguished between motor symptoms and non-motor symptoms.

Parkinson’s disease is a progressive neurological disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement, resulting in tremors, slowness of movement, rigidity, and impaired balance and coordination – the primary symptoms of the disease.

With the current practice of treating patients with Parkinson’s disease through in-person clinical examination, clinicians have only a limited amount of time available for observing and examining the patients and are heavily relying on patient reporting for symptoms and overall well-being.

The DGN-Kongress in Berlin was the venue for this year’s annual meeting of the German Neurological Society from November 8 to 11, 2023. Launching its presence in Germany, Adamant Health participated for the first time as an advanced technology provider with a booth to promote our concept for accurate and detailed symptom measurement.

We’ve just returned from this year’s International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen and are strongly encouraged by the valuable and in-depth discussions we had there. We feel it is absolutely key to continue educating the market about the EMG signal’s role in quantifying the neurophysiological basis of motor symptoms and why it provides a more accurate picture.